Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Drugmaker Shire soars as Japan's Takeda considers bid

03/28/2018 | 06:50pm EST
Logos of Japanese Takeda Pharmaceutical Co are seen at an office building in Glattbrugg

LONDON/TOKYO (Reuters) - Japan's largest drugmaker Takeda Pharmaceutical (>> Takeda Pharmaceutical Co Ltd) is considering a bid for London-listed rare disease specialist Shire (>> Shire) that could top $40 billion and spark another takeover battle in the deal-hungry pharma industry.

LONDON/TOKYO (Reuters) - Japan's largest drugmaker Takeda Pharmaceutical is considering a bid for London-listed rare disease specialist Shire that could top $40 billion and spark another takeover battle in the deal-hungry pharma industry.

Takeda said on Wednesday it was "at a preliminary and exploratory stage" of considering a bid, sending Shire's shares up as much as 26 percent. They ended 15.7 percent higher, valuing the group at around 32 billion pounds ($45 billion).

Shire sells treatments for rare diseases and attention deficit disorder. Takeda said buying it could create a global biopharmaceutical leader, boosting its position in the United States, oncology, gastrointestinal diseases and neuroscience.

The drugs industry has seen a surge in dealmaking as large players look for promising assets to improve their pipelines.

In recent months, France's Sanofi agreed to buy U.S hemophilia specialist Bioverativ for $11.6 billion and Belgium's Ablynx 3.9 billion euros. Before that, U.S.-based Celgene bagged cancer specialist Juno Therapeutics.

The prospect of a bid for Shire, 57 percent of whose employees are based in North America, immediately stoked expectations for a takeover battle.

"Takeda publicly saying it is considering an approach for Shire inevitably means that other big pharma players including AbbVie, Novartis, Pfizer et al will equally be running the numbers with a very high likelihood of leading to a competitive M&A multi-bidder situation," said Michael Wegener, managing partner at hedge fund Case Equity Partners, which has a stake in Shire.

Others shared that view.

"We expect most large pharma companies have a takeout model of Shire and the Takeda's announcement will force them to make a decision whether they want to step up," said Bernstein analyst Wimal Kapadia, also pointing to Pfizer and Abbvie, in particular.


U.S. drugmaker AbbVie in 2014 walked away from a planned $55 billion purchase of Shire after changes to U.S. tax rules that would have allowed it to take advantage of lower corporate tax rates overseas.

Analysts pointed to Shire's relatively low market value as helping to attract suitors. At 8.2 times expected core earnings, its market value including debt ranks well below most of its European peers, according to Thomson Reuters data.

Takeda said it had not approached Shire's board. Under UK takeover rules, it has until April 25 to decide whether to make a bid.

Shire said it noted Takeda's statement, and confirmed it had not received an approach.

Shire has been under pressure in the last year, with its shares down 24 percent, due to greater competition from generic drugs and a debt pile that stems from its biggest ever deal, the $32 billion acquisition of Baxalta in 2016.

The company said in January that it would run its attention deficit hyperactivity disorder (ADHD) business, which consists mainly of its blockbuster drug Vyvanse, as a distinct business and possibly seek a separate listing.


Takeda, Japan's largest drugmaker by sales, focuses its research on developing treatments for cancer and diseases of the digestive and nervous systems.

It has made no secret of its ambition to become a more global company through acquisitions, although buying Shire would be the boldest move yet by its French CEO Christophe Weber.

"Clearly defined strategic and financial objectives are core to Takeda's disciplined approach to acquisitions, including in relation to its dividend policy and credit rating, which are well-established," Takeda said in a statement.

"Any potential offer for Shire, if made, would have to align with this strict investment criteria."

The statement came after Takeda's shares had closed 1.9 percent lower on the Tokyo stock exchange.

Analysts at Deutsche Bank and Bernstein Research said, given the two companies' debt burden, Takeda is likely to make a considerable part of any bid in the form of its own shares.

Not including Wednesday's share surge, Shire is roughly on par with Takeda in terms of stock market value.

Weber, a former GSK executive, was appointed CEO in April 2015 and has already done a number of deals.

In January, Takeda agreed to buy Belgian biotech group TiGenix NV for 520 million euros, funding the deal with cash on hand, and last year, it bought U.S. cancer drug specialist Ariad for $5.2 billion. Takeda's overseas deals mirror those by other Japanese companies, which are facing bleak prospects at home as a rapidly shrinking population weighs on domestic demand.

($1 = 0.7061 pounds)

($1 = 106.2200 yen)

(Additional reporting by Ludwig Burger in Frankfurt, Rahul B in Bengaluru, Paul Sandle and Maiya Keidan in London and Ben Hirschler in New York; Editing by Keith Weir and Mark Potter)

By Kate Holton and Thomas Wilson

© Reuters 2018
Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. 0.21% 110.4956 Delayed Quote.3.13%
CELGENE 0.10% 108.24 End-of-day quote.68.89%
JUST GROUP PLC -1.66% 74.2 Delayed Quote.7.94%
ONE STOP SYSTEMS, INC. 2.74% 4.0073 Delayed Quote.-0.60%
PFIZER INC. 0.56% 37.4301 Delayed Quote.1.28%
PROSPECT CO., LTD. -3.13% 31 End-of-day quote.3.33%
SANOFI -0.23% 81.25 Real-time Quote.3.56%
SEEK LIMITED 1.26% 28.83 End-of-day quote.1.05%
STEP CO.,LTD. 0.98% 1540 End-of-day quote.-3.57%
TAKEDA PHARMACEUTICAL COMPANY LIMITED 3.54% 3714 End-of-day quote.-1.09%
THOMSON REUTERS CORPORATION -0.59% 105.19 Delayed Quote.1.64%
US DOLLAR / JAPANESE YEN (USD/JPY) -0.13% 103.609 Delayed Quote.0.58%
WILL GROUP, INC. 4.97% 1057 End-of-day quote.5.07%
06:36aTAKEDA PHARMACEUTICAL : Achieves Industry-Leading Positions in 2021 Access to Me..
01:28aJapan shares end lower on vaccine delay, caution ahead of earnings season
01/25Japan stocks slip on vaccine worries, profit-taking ahead of earnings
01/25TAKEDA PHARMACEUTICAL : Manufacturing and Marketing Approval Received in Japan f..
01/25Japanese shares gain tracking U.S. futures; tech and pharma stocks boost
01/24Japanese shares track U.S. futures higher, tech leads gains
01/24TAKEDA PHARMACEUTICAL : Named Global Top Employer for Fourth Consecutive Year
01/22TAKEDA PHARMACEUTICAL : Manufacturing and Marketing Approval Received in Japan f..
01/21TAKEDA PHARMACEUTICAL : Starts Clinical Trial of Moderna's COVID-19 Vaccine Cand..
01/21MODERNA : Says First Participant Dosed in COVID-19 Vaccine Phase 1/2 Study in Ja..
More news
Sales 2021 3 228 B 31 141 M 31 141 M
Net income 2021 202 B 1 947 M 1 947 M
Net Debt 2021 3 840 B 37 045 M 37 045 M
P/E ratio 2021 35,7x
Yield 2021 4,76%
Capitalization 5 913 B 56 976 M 57 033 M
EV / Sales 2021 3,02x
EV / Sales 2022 2,83x
Nbr of Employees 47 495
Free-Float 99,1%
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 13
Average target price 5 150,00 JPY
Last Close Price 3 782,00 JPY
Spread / Highest target 71,9%
Spread / Average Target 36,2%
Spread / Lowest Target 8,41%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Yasuhiko Yamanaka Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.46%436 949
ROCHE HOLDING AG3.82%309 894
NOVARTIS AG2.96%220 401
PFIZER INC.1.28%207 217
MERCK & CO., INC.-0.79%205 312